Susan Bobulsky, an officer of Adaptive Biotechnologies Corporation, filed a Form 144 on November 12, 2026, notifying the SEC of a proposed sale of 1,875 shares of common stock executed on November 11, 2026.

Key Highlights

  • Proposed sale: 1,875 shares of Adaptive Biotechnologies common stock with an aggregate market value of $55,050.00, according to the filing.
  • Source of shares: The securities were acquired on 03/04/2024 as Restricted Stock Units granted by the issuer, with payment date noted as 03/04/2024.
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is identified as the executing broker.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 trading plan adopted on 12/16/2025.
  • Prior sales in past three months: Bobulsky sold 6,444 shares for gross proceeds of $193,320.00 on 10/06/2026, and 1,195 shares for gross proceeds of $32,265.00 on 09/15/2026, both under a 10b5-1 plan.
  • Shares outstanding: The filing states 161,876,694 shares of common stock outstanding at the time of the notice.

Bobulsky's Proposed Sale Details and 10b5-1 Plan Background

According to the Form 144 filed with the SEC on November 12, 2026, Susan Bobulsky, identified as an officer of Adaptive Biotechnologies Corporation (NASDAQ:ADPT), proposed to sell 1,875 shares of common stock. The filing states the sale was executed on November 11, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services. The aggregate market value of the proposed sale is listed as $55,050.00.

The filing discloses that the 1,875 shares were acquired on 03/04/2024 via a Restricted Stock Unit grant from the issuer. The notice also states that Bobulsky adopted a Rule 10b5-1 trading plan on 12/16/2025, under which the proposed sale and prior recent sales were executed. The filing includes a remark explaining that "Sales that were executed on November 11, 2026 are being reported on this Form 144 filed on November 12, 2026 given the EDGAR system was not accepting filings on November 11, 2026 in observance of the federal holiday."

The filing further discloses that in the three months preceding this notice, Bobulsky sold 6,444 shares on 10/06/2026 for gross proceeds of $193,320.00, and 1,195 shares on 09/15/2026 for gross proceeds of $32,265.00, both attributed to 10b5-1 plan sales. The company is headquartered at 1165 Eastlake Avenue East, Seattle, Washington 98109, and carries SEC File Number 001-38957.

What Was Disclosed

The filing is a Form 144 notice of a proposed sale of 1,875 Adaptive Biotechnologies common shares, valued at $55,050.00, by officer Susan Bobulsky under a 10b5-1 plan adopted December 16, 2025, with the sale date reported as November 11, 2026.